ARK Genomic Revolution ETF (BATS: ARKG)
Ticker | Name | Share % | |
---|---|---|---|
TWST | Twist Bioscience Corp. | 9.60% | |
CDNA | Caredx | 7.29% | |
SM | Crispr Therapeutics Ag | 6.91% | |
RXRX | Recursion Pharmaceuticals, Inc. | 5.02% | |
IONS | Ionis Pharmaceuticals Inc | 4.88% | |
NTLA | Intellia Therapeutics | 4.74% | |
BEAM | Beam Therapeutics Inc | 4.41% | |
SDGR | Schrodinger, Inc. | 3.87% | |
ADPT | Adaptive Biotechnologies Corporation | 3.78% | |
TXG | 10X Genomics Inc | 3.61% |
The ARKG ETF is currently trading at $22.42, which represents a -3.11% change. Over the past 52 weeks, the ETF has traded as high as $32.32 and as low as $22.27.
The expense ratio of ARKG is NA%. This represents the annual fee that all funds or ETFs charge their shareholders.
The total Assets Under Management (AUM) for ARKG is 1.28B. This represents the total market value of the assets managed by the ETF.
ARKG follows a Small Cap Growth investment style.
The top holdings of ARKG include: TWST (9.6%), CDNA (7.29%), SM (6.91%), RXRX (5.02%), IONS (4.88%). These represent the largest positions in the ETF's portfolio.
Average daily volume data for ARKG is currently not available.